Pablo Lee

发表

Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer

F. Cappuzzo, E. Smit, D. Ferry, 2018, Cancer Chemotherapy and Pharmacology.

Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double‐Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation‐Positive Metastatic Non–Small‐Cell Lung Cancer

L. Paz-Ares, M. Reck, K. Nakagawa, 2017, Clinical lung cancer.

Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology

A. Brnabic, L. Hess, S. Barker, 2019, Journal of Cancer.

East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)

J. Shih, Keunchil Park, E. Cho, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.

F. Cappuzzo, K. Syrigos, Michael Thomas, 2016, Lung cancer.

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group.

B. Jeremic, L. Collette, J. Pignon, 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group.

B. Jeremic, L. Collette, J. Pignon, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Exposure-response relationship for ramucirumab (RAM) from the randomized, double-blind, phase III REVEL trial (docetaxel [DOC] vs DOC plus RAM) in second-line treatment of metastatic non-small cell lung cancer (NSCLC).

F. Cappuzzo, E. Smit, D. Ferry, 2015 .

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

R. Doebele, E. Berge, D. Camidge, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.

K. Kiura, L. Paz-Ares, M. Reck, 2017, Clinical lung cancer.

Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second‐Line Treatment of Advanced Non–Small‐Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial

E. Cho, S. Ramalingam, S. Dakhil, 2017, Clinical lung cancer.

Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.

F. Cappuzzo, Michael Thomas, F. Shepherd, 2017, Lung cancer.

A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.

Y. Hosomi, Y. Ohe, K. Yoh, 2016, Lung cancer.

Incidence and Management of Olaratumab Infusion-Related Reactions

W. Tap, B. V. Van Tine, V. Wacheck, 2019, Journal of oncology practice.

Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.

K. Syrigos, Keunchil Park, L. Paz-Ares, 2017, Lung cancer.

3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy

M. Socinski, G. Scagliotti, D. Ferry, 2015 .

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy

M. Socinski, G. Scagliotti, Michael Thomas, 2020, ESMO Open.

Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.

M. Socinski, J. Shih, F. Shepherd, 2018, Lung cancer.

Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC).

K. Syrigos, Keunchil Park, L. Paz-Ares, 2015 .

Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).

F. Cappuzzo, F. Shepherd, A. Tsao, 2016 .

OA11.02 Randomized Phase 1b/3 Study of Erlotinib plus Ramucirumab in First-Line EGFR Mut + Stage IV NSCLC: Phase 1b Safety Results

K. Kiura, L. Paz-Ares, M. Reck, 2017 .